Abstract
Blood circulating endothelial cells and circulating hematopoietic progenitor cells (CPCs) are two cell populations that are thought to play important role in angiogenesis. In the present study, we investigated the role of CPCs in patients with brain tumors. We prospectively studied 19 brain tumor patients. Ten healthy individuals were used as controls. Variables that were analyzed included age, sex, Ki-67 index, symptom duration, tumor location, tumor size and preoperative Karnofsky performance status score (KPS). CPCs were determined as CD45dim/CD34+/CD133+ in the peripheral blood. Twelve patients had glioblastoma (GBM), 1 patient had a grade II glioma and 6 patients had meningioma. Brain tumor patients had significantly higher CPC levels compared to healthy volunteers. Patients with gliomas had significantly higher CPC levels than patients with meningiomas. In GBM patients no correlation was found between CPC levels and sex, age, Ki-67 index, tumor location, size and KPS. Patients with CPC levels lower than 1,743 cells/ml had a higher progression-free survival but the difference was not statistically significant. Glioma patients had higher CPC levels compared to patients with meningiomas. Larger studies are obviously needed to verify the role of CPC levels in patients with brain tumors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Goon PK, Lip GY, Boos CJ, Stonelake PS, Blann AD (2006) Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia 8:79–88
Wojakowski W, Kucia M, KaŸmierski M, Ratajczak MZ, Tendera M (2008) Circulating progenitor cells in stable coronary heart disease and acute coronary syndromes: relevant reparatory mechanism? Heart 94:27–33
Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Böhm M, Nickenig G (2005) Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 353:999–1007
Rafat N, Beck GCh, Schulte J, Tuettenberg J, Vajkoczy P (2010) Circulating endothelial progenitor cells in malignant gliomas. J Neurosurg 112:43–49
Greenfield JP, Jin DK, Young LM, Christos PJ, Abrey L, Rafii S, Gutin PH (2009) Surrogate markers predict angiogenic potential and survival in patients with glioblastoma multiforme. Neurosurgery 64:819–826
Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83–95
Kothari RU, Brott T, Broderick JP, Barsan WG, Sauerbeck LR, Zuccarello M, Khoury J (1996) The ABCs of measuring intracerebral hemorrhage volumes. Stroke 27:1304–1305
Duda DG, Cohen KS, Scadden DT, Jain RK (2007) A protocol for phenotypic detection enumeration of circulating endothelial cells and circulating progenitor cells in human blood. Nat Protoc 2:805–810
Goon PK, Lip GY, Stonelake PS, Blann AD (2009) Circulating endothelial cells and circulating progenitor cells in breast cancer: relationship to endothelial damage/dysfunction/apoptosis, clinicopathologic factors, and the Nottingham Prognostic Index. Neoplasia 11:771–779
Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964–967
Chen MC, Yip HK, Chen CJ, Yang CH, Wu CJ, Cheng CI, Chen YH, Chai HT, Lee CP, Chang HW (2006) No age-related change in circulating endothelial progenitor cells in healthy subjects. Int Heart J 47:95–105
Bellows CF, Zhang Y, Simmons PJ, Khalsa AS, Kolonin MG (2011) Influence of BMI on level of circulating progenitor cells. Obesity (Silver Spring) 19:1722–1726
Yao Y, Kubota T, Takeuchi H, Sato K (2005) Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody. Neuropathology 25:201–206
Moschovi M, Koultouki E, Stefanaki K, Sfakianos G, Tourkantoni N, Prodromou N, Alexiou GA (2011) Prognostic significance of angiogenesis in relation to Ki-67, p-53, p-27, and bcl-2 expression in embryonal tumors. Pediatr Neurosurg 47:241–247
Vredenburgh JJ, Desjardins A, Reardon DA, Peters KB, Herndon JE 2nd, Marcello J, Kirkpatrick JP, Sampson JH, Bailey L, Threatt S, Friedman AH, Bigner DD, Friedman HS (2011) The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res 17:4119–4124
Gerstner ER, Batchelor TT (2012) Antiangiogenic therapy for glioblastoma. Cancer J 18:45–50
Takano S, Yoshii Y, Kondo S, Suzuki H, Maruno T, Shirai S, Nose T (1996) Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res 56:2185–2190
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Alexiou, G.A., Vartholomatos, G., Karamoutsios, A. et al. Circulating progenitor cells: a comparison of patients with glioblastoma or meningioma. Acta Neurol Belg 113, 7–11 (2013). https://doi.org/10.1007/s13760-012-0097-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13760-012-0097-y